Principal Financial Group Inc. grew its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 347.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 52,734 shares of the medical research company’s stock after purchasing an additional 40,936 shares during the period. Principal Financial Group Inc. owned about 0.06% of NeoGenomics worth $665,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. CWM LLC acquired a new stake in shares of NeoGenomics during the 4th quarter worth approximately $30,000. Ruggie Capital Group boosted its position in shares of NeoGenomics by 74.1% during the 4th quarter. Ruggie Capital Group now owns 2,350 shares of the medical research company’s stock worth $30,000 after acquiring an additional 1,000 shares in the last quarter. First Quadrant L P CA acquired a new stake in shares of NeoGenomics during the 4th quarter worth approximately $65,000. Quantamental Technologies LLC acquired a new stake in shares of NeoGenomics during the 4th quarter worth approximately $76,000. Finally, Bessemer Group Inc. acquired a new stake in shares of NeoGenomics during the 4th quarter worth approximately $78,000. Hedge funds and other institutional investors own 77.00% of the company’s stock.

NEO has been the topic of several analyst reports. BidaskClub upgraded shares of NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 20th. Zacks Investment Research lowered shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Needham & Company LLC raised their target price on shares of NeoGenomics from $19.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, March 29th. ValuEngine upgraded shares of NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 10th. Finally, CIBC upgraded shares of NeoGenomics from a “neutral” rating to an “outperform” rating and cut their target price for the company from $18.00 to $15.00 in a research report on Tuesday, March 12th. One research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. NeoGenomics currently has a consensus rating of “Buy” and a consensus target price of $19.55.

In other news, VP Jennifer Balliet sold 30,000 shares of the firm’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $19.57, for a total transaction of $587,100.00. Following the completion of the transaction, the vice president now owns 40,000 shares of the company’s stock, valued at $782,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Robert J. Shovlin sold 186,014 shares of the firm’s stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $18.96, for a total transaction of $3,526,825.44. Following the transaction, the insider now directly owns 40,166 shares of the company’s stock, valued at approximately $761,547.36. The disclosure for this sale can be found here. Insiders sold 263,524 shares of company stock worth $5,019,496 in the last 90 days. Company insiders own 12.20% of the company’s stock.

Shares of NeoGenomics stock opened at $19.66 on Monday. NeoGenomics, Inc. has a fifty-two week low of $9.08 and a fifty-two week high of $22.17. The company has a current ratio of 1.70, a quick ratio of 1.56 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of 151.23 and a beta of 0.93.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, February 19th. The medical research company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. NeoGenomics had a net margin of 0.95% and a return on equity of 2.25%. The firm had revenue of $76.50 million for the quarter, compared to analyst estimates of $71.29 million. During the same quarter last year, the business posted $0.05 earnings per share. The company’s quarterly revenue was up 24.6% on a year-over-year basis. Equities analysts anticipate that NeoGenomics, Inc. will post 0.18 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Principal Financial Group Inc. Has $665,000 Holdings in NeoGenomics, Inc. (NEO)” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/principal-financial-group-inc-has-665000-holdings-in-neogenomics-inc-neo/2980664.html.

NeoGenomics Company Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Further Reading: What is an SEC Filing?

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.